Supporting Information

Total Page:16

File Type:pdf, Size:1020Kb

Supporting Information Supporting Information Lehmann et al. 10.1073/pnas.1409026111 SI Materials and Methods Metaiodobenzylguanidine-PET. All chemicals were purchased from fl/fl – 124 Experimental Animals. Conditional ETA KO mice (ETA ) Sigma Aldrich unless otherwise noted. I was purchased from were described previously (1). ETAfl/fl were crossed with trans- Eckert & Ziegler. Poly-(3-{dibutyl[2-(3-and-4-vinylphenyl)ethyl] genic mice overexpressing Cre recombinase under the control of stannyl}benzylguanidinium acetate)-codivinylbenzene, a tin pre- cursor anchored to a polystyrene matrix, was obtained from the dbh promoter, DBH-Cre (2), to obtain mice lacking ETA only in SNs (ETAfl/fl;DBH-Cre, abbreviated as SN-KO) or under Molecular Insight Pharmaceuticals. High-performance liquid chro- the control of the myh6 promoter, αMHC-Cre (3), to obtain mice matography gamma was performed using an Agilent 1100 HPLC fl/fl equipped with a Raytest (Germany) Model Gabi radioisotope de- lacking ETA only in CMs (ETA ;αMHC-Cre, abbreviated as CM-KO). Control littermates (Ctrl. LM) consisted of ETAfl/fl, tector. Analytical reversed-phase HPLC (RP-HPLC) analyses were + + + + + ETA /fl,ETA / ,andETA / ;DBH-Cre littermates for SN- performed using a Chromolith Performance RP-18 endcapped + + + + + column (3 × 100 mm). The column was eluted in a linear gradient KO and ETAfl/fl,ETA/fl, ETA / , and ETA / ;αMHC-Cre (0–100%) of acetonitrile [0.1% trifluoroacetic acid (TFA)] in water littermates for CM-KO. All these mouse lines and Dahl salt- (0.1% TFA) for 5 min; flow rate of 2 mL/min; and room temper- resistant (DR), Dahl salt-sensitive (DS), Sprague–Dawley, and 124 ature absorbance λ = 214 nm. [ I]Metaiodobenzylguanidine Wistar rats (Charles River Laboratories) were housed under (MIBG) synthesis was conducted as follows: 3.2 mg of the resin standard conditions and maintained on commercial mouse or rat was swollen for 5 min in 50 μL ethanol, and 25 μL of water was chow and water ad libitum. The environment was maintained at added; 120 MBq [124I] in a volume of 35 μL was added, followed – 22 °C with a 12-h light 12-h dark cycle. For preparation of by 25 μL of a solution of hydrogen peroxide in acetic acid. The neonatal CMs or SNs, pups were killed between days 1 and 3 pH value of the reaction mixture was pH 4. The reaction mixture postnatal. Male DR and DS (9 wk of age; mean weight, 200 g; was stirred at a temperature of 85 °C for 20 min. At this time, M&B) were fed on a high-salt diet [8% (vol/vol) NaCl] for 40 d. HPLC analysis revealed a complete conversion, and 20 μLof Treated DS rats received darusentan (30 mg/kg/d; DS + DA in a saturated solution of methionine in water was added to quench the drinking water (was changed twice the day) with onset of the the reaction. The resin was separated by filtration over a sterile diet. Water and drug intake was controlled on a daily basis. filter and washed with 0.9% NaCl. The mixture was neutralized with 35 μL of 1 M NaOH, and the pH was adjusted to 7.4 with Transverse Aortic Constriction. Transverse aortic constriction (TAC) phosphate buffer. Radio-HPLC revealed the purity (>95%) of was performed in 9- to 10-wk-old male SN-KO and CM-KO and the product. Mice were measured 7 wk after TAC surgery 1 h control littermates from the same strain as described previously after i.v. injection of 10.73 ± 0.69 MBeq of [124I]-MIBG. The (4, 5). Briefly, the animals were anesthetized with ketamine anesthetized animals [2% (vol/vol) sevoflurane; Abbott] were (120 mg/kg, i.p.) and xylazine (15 mg/kg, i.p.). The mice were placed in an Inveon small animal PET scanner (Siemens). Re- orally intubated with 20-gauge tube and ventilated (Harvard gion of interest (ROI) analysis of the acquired images was per- Apparatus) at 120 breaths/min (0.2-mL tidal volume). The aortic formed using Siemens imaging software. The resulting image constriction was created via a lateral thoracotomy through the data were normalized to the administered activity to parame- second intercostal space. A suture (Prolene 7-0) was placed terize the microPET images in terms of %ID/g (percentage of around the transverse aorta between the brachiocephalic and left injected dose per gram of heart corrected for radioactive decay carotid artery. The suture was ligated against a 27-gauge needle. to the time of injection). The uptake profiles were fitted to The needle was removed, leaving a discrete stenosis. Afterward, a one-compartment model (realized with the PMOD software) the chest was closed. Integrity of aortic banding was confirmed to estimate the influx rate constant (K1, milliliters of medium per by inspection of the surgical constriction and by visualization of grams of cells per min), and the volume of distribution (Vd). marked differences in the caliber of the right and left carotid arteries in TAC (6). A sham procedure in which the thoracic Heart Tissue Preparation. Mice were killed by cervical dislocation, aorta was not banded was also performed. Mice were killed from and hearts were removed and weighed promptly. Relative heart weight was calculated as ratio to body weight. The left ventricles about 7 wk after surgery. were transversely dissected, and parts of the left ventricles were Echocardiography. For measurements of chamber dimensions and quickly frozen in liquid nitrogen for protein and RNA isolation calculation of fractional shortening or ejection fraction, we used and analysis. Some hearts were arrested in diastole and com- a Tracing software from VisualSonics on the parasternal long axis pletely fixed for 48 h in 4% (vol/vol) paraformaldehyde dissolved × − in 0.1 M PBS (pH 7.4), embedded in paraffin, longitudinally cut via the following formula: 100 [(LVEDV LVESV)/LVEDV)], μ where LVEDV is left ventricular end-diastolic volume and LVESD into 5- m sections, and stained for histomorphometry. is left ventricular end-systolic volume. To quantify the stenosis Primer for RNA Analysis. The primers and probes that were used are after TAC surgery, echocardiographic data were achieved at heart as follows—rat: myh6 sense 5′-tgcagaagaaactgaaggaaaa-3′ and rates between 450 and 550 beats/min, and the evaluation was per- antisense 5′-gctcggcctctagctcct-3′; myh7 sense 5′-caccaacaaccc formed with short-acting isoflurane anesthesia. Arterial blood ctacgatt-3′ and antisense 5′-agcacatcaaaggcgctatc-3′; th sense pressure of awake animals and left ventricular/intraventricular 5′-tctccctgaggggtacaaaa-3′ and antisense 5′-gaattttggcttcaa pressure were recorded as previously described in detail (7). Left atgtctca-3′;mouse:ednra sense 5′-tgtgagcaagaaattcaaaaattg-3′ ventricular end-diastolic pressure (LVEDP), left ventricular con- and antisense 5′-atgaggcttttggactggtg-3′; nppa sense 5′-cacaga + – tractility [( )dP/dtmax], and left ventricular relaxation [( )dP/dtmax] tctgatggatttcaaga-3′ and antisense 5′-cctcatcttctaccggcatc-3′; were calculated using chart software package (ADInstruments col3a1 sense 5′-tcccctggaatctgtgaatc-3′ and antisense 5′-tgagtcg Pty. Ltd.). Transthoracic echocardiography was performed as aattggggagaat-3′; myh7 sense 5′-cgcatcaaggagctcacc-3′ and an- previously described in detail (8). The investigator conducting tisense 5′-ctgcagccgcagtaggtt-3′; gapdh sense 5′-gggttcctataaa- the echocardiography was blinded to the treatment status. tacggactgc-3′ and antisense 5′-ccattttgtctacgggacga-3′; th sense 5′- Lehmann et al. www.pnas.org/cgi/content/short/1409026111 1of9 cccaagggcttcagaagag-3′ and antisense 5′-gggcatcctcgatgagact-3′.For nM ET1 for 18–24 h. Murine CMs were isolated from neonatal SERCA (atp2a2) we used a taqman universal PCR mastermix ETAfl/fl mice as described previously (14). Pups were decapi- (Applied Biosystems). tated, and ventricular tissue was carefully dissected and disso- ciated in 0.41 mg/mL collagenase (Sigma) and 0.30 mg/mL Isolated Heart Perfusion. Wistar rats were anesthetized with thio- pancreatin (Sigma) in Ads buffer (116 mM NaCl, 20 mM pental (100 mg/kg, i.p.). The hearts were rapidly cut out and Hepes, 0.8 mM NaH2PO4,1g/literglucose,5.4mMKCl,and rinsed in ice-cold buffer, and the aorta was cannulated for per- 0.8 mM MgSO4, pH 7.35). CMs were plated on laminin/poly-L- fusion according to the Langendorff method. Within one ex- lysine–coated plates, and cells were treated with adenovirus – periment, 8 12 spontaneously beating hearts were perfused expressing Cre-recombinase (a kind gift by Oliver Müller, Uni- simultaneously at a constant coronary flow and a constant tem- versity Hospital, Heidelberg, Germany) for 12 h with 12 multi- perature of 37.5 °C. The perfusion medium was a modified Krebs- plicity of infection (MOI). For CM-SN coculture, neonatal rat Henseleit solution (125 mmol/L NaCl, 16.9 mmol/L NaHCO3, SNs were plated 1 d after preparation of CMs. After 3 d, medium 0.2 mmol/L Na2HPO4, 4.0 mmol/L KCl, 1.85 mmol/L CaCl2, 1.0 was changed to serum-free medium for 24 h. For hypertrophic mmol/L MgCl2, 11 mmol/L glucose, and 0.027 mmol/L EDTA). experiments, cells were then treated with 10 nM ET1 for 18–24 h The buffer was gassed with 95% (vol/vol) O2 and 5% (vol/vol) 3 before measurement of fixation. CO2, and the pH was adjusted to 7.4. Cardiac [ H]-norepi- nephrine (NE) uptake was determined as described previously Plasmids and Reagents. CMs were transduced with adenoviruses 3 μ (9). Briefly, a bolus of [ H]-NE (1 mL, 3 Ci, 100 pmol NE; harboring FLAG-HDAC4 (Ad-HDAC4), and FLAG-HDAC5 Amersham-Buchler) was injected into the perfusion system and (Ad-HDAC5) were infected for 24 h as described previously (13), proportionally distributed to the hearts and blank channels. 3 starved for 4 h, and stimulated with 10 nM ET1 for 12 h.
Recommended publications
  • Endothelin System and Therapeutic Application of Endothelin Receptor
    xperim ACCESS Freely available online & E en OPEN l ta a l ic P in h l a C r m f o a c l a o n l o r g u y o J Journal of ISSN: 2161-1459 Clinical & Experimental Pharmacology Research Article Endothelin System and Therapeutic Application of Endothelin Receptor Antagonists Abebe Basazn Mekuria, Zemene Demelash Kifle*, Mohammedbrhan Abdelwuhab Department of Pharmacology, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia ABSTRACT Endothelin is a 21 amino acid molecule endogenous potent vasoconstrictor peptide. Endothelin is synthesized in vascular endothelial and smooth muscle cells, as well as in neural, renal, pulmonic, and inflammatory cells. It acts through a seven transmembrane endothelin receptor A (ETA) and endothelin receptor B (ETB) receptors belongs to G protein-coupled rhodopsin-type receptor superfamily. This peptide involved in pathogenesis of cardiovascular disorder like (heart failure, arterial hypertension, myocardial infraction and atherosclerosis), renal failure, pulmonary arterial hypertension and it also involved in pathogenesis of cancer. Potentially endothelin receptor antagonist helps the treatment of the above disorder. Currently, there are a lot of trails both per-clinical and clinical on endothelin antagonist for various cardiovascular, pulmonary and cancer disorder. Some are approved by FAD for the treatment. These agents are including both selective and non-selective endothelin receptor antagonist (ETA/B). Currently, Bosentan, Ambrisentan, and Macitentan approved
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0116357 A1 Fushimi Et Al
    US 2004O116357A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0116357 A1 Fushimi et al. (43) Pub. Date: Jun. 17, 2004 (54) GLUCOPYRANOSYLOXYPYRAZOLE DERVATIVES AND MEDICINAL USE THEREOF (I) (76) Inventors: Nobuhiko Fushimi, Matsumoto-shi (JP); Hideki Fujikura, Matsumoto-shi (JP); Toshihiro Nishimura, Minamiazumi-gun (JP); Kenji Katsuno, Kamiina-gun (JP); Masayuki Isaji, Shiojiri-shi (JP) Correspondence Address: SUGHRUE MION, PLLC 2100 PENNSYLVANIAAVENUE, N.W. SUTE 800 WASHINGTON, DC 20037 (US) (21) Appl. No.: 10/469,140 (22) PCT Filed: Feb. 26, 2002 (86) PCT No.: PCT/JP02/01708 wherein R', R and R represent a hydrogen atom or a (30) Foreign Application Priority Data halogen atom; R" represents a lower alkyl group or a halo(lower alkyl) group; and R represents a hydrogen atom, Feb. 27, 2001 (JP)...................................... 2001-053085 a lower alkyl group, a lower alkoxy group, a lower alkylthio group, etc., a pharmaceutically acceptable Salt thereof or a Publication Classification prodrug thereof., which exert an excellent inhibitory activity (51) Int. Cl. ................................................ A61K 31/7056 in human SGLT2, and therefore are useful as drugs for the (52) U.S. Cl. ............................................. 514/23: 536/17.4 prevention or treatment of a disease associated with hyper glycemia Such as diabetes, diabetic complications or obesity, (57) ABSTRACT pharmaceutically acceptable Salts thereof or prodrugs The present invention provides glucopyranosyloxypyrazole thereof, production intermediates thereof and pharmaceuti derivatives represented by the general formula: cal uses thereof. US 2004/0116357 A1 Jun. 17, 2004 GLUCOPYRANOSYLOXYPYRAZOLE 0005. In recent years, development of new type antidia DERVATIVES AND MEDICINAL USE THEREOF betic agents has been progressing, which promote urinary glucose excretion and lower blood glucose level by prevent TECHNICAL FIELD ing excess glucose reabsorption at the kidney (J.
    [Show full text]
  • Supplementary Information
    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
    [Show full text]
  • (12) United States Patent )-X- NZ
    US008895596B2 (12) United States Patent (10) Patent No.: US 8,895,596 B2 Jiang et al. (45) Date of Patent: Nov. 25, 2014 (54) CYCLIC BENZMDAZOLE DERVATIVES (56) References Cited USEFUL AS ANT-DABETICAGENTS U.S. PATENT DOCUMENTS (75) Inventors: Jinlong Jiang, Scotch Plains, NJ (US); 5,596,025 A 1/1997 Oxman et al. Andrew J. Kassick, Scotch Plains, NJ 6,312,662 B1 11/2001 Erion et al. (US); Ahmet Kekec, Jersey City, NJ 6,489.476 B1 12/2002 Dang et al. (US); Iyassu K. Sebhat, Jersey City, NJ 7,098,220 B2 8, 2006 Rault et al. 7,268,145 B2 9, 2007 Matsumoto et al. (US) 2005, OO38068 A1 2/2005 Iyengar et al. 2005.0113283 A1 5/2005 Solow-Cordero et al. (73) Assignee: Merck Sharp & Dohme Corp, Rahway, 2005. O148643 A1 7/2005 Rui et al. NJ (US) 2005/O187277 A1 8/2005 Malti et al. 2005/0255415 A1 11/2005 Louwet et al. (*) Notice: Subject to any disclaimer, the term of this 2005/0272765 A1 12/2005 Feng et al. patent is extended or adjusted under 35 2006.0160872 A1 7/2006 Norman et al. 2006/0287356 Al 12/2006 Iyengaret al. U.S.C. 154(b) by 0 days. 2007, OO15665 A1 1/2007 Potluri et al. 2007/0O32529 A1 2/2007 Takagi et al. (21) Appl. No.: 13/578,302 2008. O1325O1 A1 6/2008 Sun et al. (22) PCT Fled: Feb. 21, 2011 FOREIGN PATENT DOCUMENTS (86) PCT NO.: PCT/US2011/025585 DE 33 16095 A1 11, 1983 EP O120403 A2 10, 1984 S371 (c)(1), EP O126030 A2 11, 1984 (2), (4) Date: Aug.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • I Regulations
    23.2.2007 EN Official Journal of the European Union L 56/1 I (Acts adopted under the EC Treaty/Euratom Treaty whose publication is obligatory) REGULATIONS COUNCIL REGULATION (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 THE COUNCIL OF THE EUROPEAN UNION, (4) In the course of three such reviews it was concluded that a certain number of additional INNs and intermediates used for production and manufacture of finished pharmaceu- ticals should be granted duty-free treatment, that certain of Having regard to the Treaty establishing the European Commu- these intermediates should be transferred to the list of INNs, nity, and in particular Article 133 thereof, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded. Having regard to the proposal from the Commission, (5) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (1) established the Combined Nomenclature Whereas: (CN) and set out the conventional duty rates of the Common Customs Tariff. (1) In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty- (6) Regulation (EEC) No 2658/87 should therefore be amended free treatment should be granted to pharmaceutical accordingly, products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active HAS ADOPTED THIS REGULATION: ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation, specified salts, esters or hydrates of such INNs, and designated inter- Article 1 mediates used for the production and manufacture of finished products.
    [Show full text]
  • Product Data Sheet
    Inhibitors Product Data Sheet Sitaxsentan sodium • Agonists Cat. No.: HY-11103 CAS No.: 210421-74-2 Molecular Formula: C₁₈H₁₄ClN₂NaO₆S₂ • Molecular Weight: 476.89 Screening Libraries Target: Endothelin Receptor Pathway: GPCR/G Protein Storage: Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month SOLVENT & SOLUBILITY In Vitro DMSO : 100 mg/mL (209.69 mM; Need ultrasonic) H2O : 100 mg/mL (209.69 mM; Need ultrasonic) Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 2.0969 mL 10.4846 mL 20.9692 mL Stock Solutions 5 mM 0.4194 mL 2.0969 mL 4.1938 mL 10 mM 0.2097 mL 1.0485 mL 2.0969 mL Please refer to the solubility information to select the appropriate solvent. In Vivo 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.24 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.24 mM); Clear solution BIOLOGICAL ACTIVITY Description Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) is an orally active, highly selective antagonist of endothelin A receptors. In Vitro Sitaxsentan and Bosentan attenuate NTCP transport at higher concentrations, and inhibit human hepatic transporters, which provides a potential mechanism for the increased hepatotoxicity observed for these agents in the clinical setting. Only sitaxsentan decreased OATP transport (52%)[1]. Sitaxsentan and sitaxsentan combined with sildenafil completely prevent the increased expressions of endothelin-1 and of the ETB receptor.
    [Show full text]
  • Advice Concerning the Addition of Certain Pharmaceutical Products
    U.S. International Trade Commission COMMISSIONERS Daniel R. Pearson, Chairman Shara L. Aranoff, Vice Chairman Jennifer A. Hillman Stephen Koplan Deanna Tanner Okun Charlotte R. Lane Robert A. Rogowsky Director of Operations Karen Laney-Cummings Director of Industries Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Advice Concerning the Addition of Certain Pharmaceutical Products and Chemical Intermediates to the Pharmaceutical Appendix to the Harmonized Tariff Schedule of the United States Investigation No. 332--476 Publication 3883 September 2006 This report was prepared principally by Office of Industries Philip Stone, Project Leader With assistance from Elizabeth R. Nesbitt Primary Reviewers David G. Michels, Office of Tariff Affairs and Trde Agreements, John Benedetto, and Nannette Christ, Office of Economics Administrative Support Brenda F. Carroll Under the direction of Dennis Rapkins, Chief Chemicals and Textiles Division ABSTRACT Under the Pharmaceutical Zero-for-Zero Initiative, which entered into force in 1995, the United States and its major trading partners eliminated tariffs on many pharmaceuticals, their derivatives, and certain chemical intermediates used to make pharmaceuticals. The U.S. list of pharmaceutical products and chemical intermediates eligible for duty-free treatment under the agreement is given in the Pharmaceutical Appendix to the Harmonized Tariff Schedule of the United States. The Pharmaceutical Appendix is periodically updated to provide duty relief for additional such products, including newly developed pharmaceuticals. This report provides advice on the third update to the agreement, in which approximately 1,300 products are proposed to receive duty-free treatment.
    [Show full text]
  • CPU0213, a Novel Endothelin Type a and Type B Receptor Antagonist, Protects Against Myocardial Ischemia/Reperfusion Injury in Rats
    ISSN 0100-879X Volume 44 (11) 1070-1193 November 2011 BIOMEDICAL SCIENCES AND www.bjournal.com.br CLINICAL INVESTIGATION Braz J Med Biol Res, November 2011, Volume 44(11) 1148-1155 doi: 10.1590/S0100-879X2011007500119 CPU0213, a novel endothelin type A and type B receptor antagonist, protects against myocardial ischemia/reperfusion injury in rats Z.Y. Wang, W. Zhang, X.Z. Li, Y. Han, Y.P. Chen, Z. Liu, L.P. Xie, Y. Ji and X. Lu The Brazilian Journal of Medical and Biological Research is partially financed by Institutional Sponsors Explore High - Performance MS Orbitrap Technology In Proteomics & Metabolomics Campus Ribeirão Preto Faculdade de Medicina de Ribeirão Preto analiticaweb.com.br S C I E N T I F I C All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License Brazilian Journal of Medical and Biological Research (2011) 44: 1148-1155 ISSN 0100-879X CPU0213, a novel endothelin type A and type B receptor antagonist, protects against myocardial ischemia/reperfusion injury in rats Z.Y. Wang1, W. Zhang2, X.Z. Li2, Y. Han3, Y.P. Chen1, Z. Liu2, L.P. Xie2, Y. Ji2 and X. Lu1 1Department of Geriatrics, the Second Affiliated Hospital, 2Key Laboratory of Human Functional Genomics, Atherosclerosis Research Centre, 3Department of Geriatrics, the First Affiliated Hospital, Nanjing Medical University, Nanjing, China Abstract The efficacy of endothelin receptor antagonists in protecting against myocardial ischemia/reperfusion (I/R) injury is controversial, and the mechanisms remain unclear. The aim of this study was to investigate the effects of CPU0123, a novel endothelin type A and type B receptor antagonist, on myocardial I/R injury and to explore the mechanisms involved.
    [Show full text]
  • 09-002 Phrma Heartdis09
    201R1e port M EDICINES IN D EVELOPMENT FOR Heart Disease and Stroke PRESENTED BY AMERICA ’ S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Research Companies Are Developing Nearly 300 Medicines for Cardiovascular Disease iopharmaceutical research companies are MEDICINES IN DEVELOPMENT FOR HEART DISEASE AND STROKE * developing 299 new medicines for two of the Bleading causes of death of Americans—heart disease Acute Cor onary Syndrome 22 and stroke. The work continues the momentum of drug Adjunctive Therapies 5 Arrhythmia/Atrial Fibrillation 15 discovery that has helped cut deaths from these diseases Atherosclerosis 15 by 28 percent between 1997 and 2007. All of the medicines Coronary Artery Disease 9 are either in clinical trials or awaiting review by the Heart Attack 17 Food and Drug Administration. Heart Failure 36 Hypertension 27 According to the National Center for Health Statistics, Imaging Agents 11 heart disease has topped the list of killer diseases every Ischemic Disorders 23 43 year but one since 1900. (The exception was 1918, Lipid Disorders Peripheral Vascular Disease 20 when an influenza epidemic killed more than 450,000 Pulmonary Vascular Disease 17 Americans.) Stroke 27 Thrombosis 28 Thanks in large part to new drug treatments, death rates Other 35 from heart disease and stroke are falling. In 2008, stroke dropped to the fourth leading cause of death after being *S ome medicines are listed in more than one category. the third for over 50 years. According to the National Heart, Lung and Blood Institute (NHLBI), if death rates The medicines in development include 43 for lipid were the same as those of 30 years ago, 815,000 more disorders, such as high cholesterol, 36 for heart failure, Americans would die of heart disease annually and 27 for high blood pressure, 17 for heart attacks, and 250,000 more would die of stroke.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • REVIEW Pharmacotherapy for Meconium Aspiration
    Journal of Perinatology (2008) 28, S72–S78 r 2008 Nature Publishing Group All rights reserved. 0743-8346/08 $30 www.nature.com/jp REVIEW Pharmacotherapy for meconium aspiration A Asad and R Bhat Division of Neonatology, Department of Pediatrics, University of Illinois at Medical Center, Chicago, IL, USA with moderate-to-severe MAS. Figure 1 shows the schema of our In this article we have attempted to review the current pharmacological presentation. treatment options for infants with meconium aspiration syndrome with or The treatment options can be divided into general or specific. without persistent pulmonary hypertension. These treatments include The general treatment options are the optimization of ventilation, ventilatory support, surfactant treatment and inhaled nitric oxide (INO), in sedation and alkalanization. The more specific pharmacological addition to older and newer pharmacological treatments. These include therapies are aimed at reducing hypoxia with the use of pulmonary sedatives, muscle relaxants, alkali infusion, antibiotics and the newer vasodilators (inhaled nitric oxide (INO), oral sildenafil and vasodilators. Many aspects of treatment, including ventilatory care, bosentan), and the lung injury by anti-inflammatory agents, surfactant treatment and the use of INO, are reviewed in great detail in this surfactant lavage or replacement. issue. On the other hand, many newer pharmacological modalities of treatment described here have not been evaluated with randomized control trials. We have given an overview of these emerging therapies. Journal of Perinatology (2008) 28, S72–S78; doi:10.1038/jp.2008.160 General management In all newborns with evidence of severe respiratory distress handling is minimized to prevent worsening of gas exchange due to agitation.
    [Show full text]